The US Food and Drug Administration (FDA) has granted approval to France-based Sanofi for its blood-disorder drug Cablivi (caplacizumab-yhdp), it was reported yesterday.
The product has been approved in combination with plasma exchange and immunosuppression to treat acquired thrombotic thrombocytopenic purpura in adults. The product is said to be the first FDA-approved therapy for the treatment of acquired thrombotic thrombocytopenic purpura. It targets von Willebrand factor (vWF), a protein in the blood that involves in haemostasis. It has been designed to inhibit the interaction between vWF and platelets.
The product's approval was based on data from the Hercules multicentre, randomised, double-blind, placebo-controlled phase three clinical study. The company said that the treatment with Cablivi in combination with plasma exchange and immunosuppression resulted in a significantly shorter time to platelet count response against plasma exchange and immunosuppression alone, which is a primary efficacy endpoint.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial